NCT00092183View on ClinicalTrials.gov

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

PHASE4CompletedINTERVENTIONAL
Enrollment

866

Participants

Timeline

Start Date

October 10, 2002

Primary Completion Date

December 1, 2003

Study Completion Date

February 11, 2004

Conditions
NauseaVomitingBreast Neoplasms
Interventions
DRUG

MK0869, aprepitant / Duration of Treatment: 3 days

DRUG

Comparator: ondansetron / Duration of Treatment: 3 days

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00092183 - An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071) | Biotech Hunter | Biotech Hunter